Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
GLP-1 agonists is currently approved as second/third-line therapy for T2DM patients with inadequate glycaemic control (HbA1c 7.0 or 53 mmol/mol) despite lifestyle modifications and first-line antihyperglycaemics (metformin/sulfonylurea/insulin)
2014;10(1 Suppl):S2632
Understanding the eligibility criteria before you start the signup process saves time and potential frustration
This dual action makes Semaglutide a popular choice for both weight loss and diabetes management
A food-first approach is always preferable: prioritising a varied, nutrient-dense diet should be the primary strategy
Eat a protein-rich diet
